[1] |
MENG Kangkang, LIU Saiyue.
After-marketing safety of coenzyme Q10 for injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 795-798.
|
[2] |
PANG Yu, ZHU Lan, WANG Tao, YU Hongli, SHAO Bo, LIU Bo.
Analysis of Risks of Longbishu Preparation
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 869-871.
|
[3] |
CONG Duanduan, XUE Wei, LIU Yue, QI Wenyuan, LIU Xiaohui, WANG Juan, LI Kexin, HU Xin.
Management of Safety Information in Prescription Drug Labeling in China, Japan and the United States
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 245-249.
|
[4] |
XU Shungui, LIU Chunguang.
Survey of the Regulation System of OTC Drugs in the United States
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 141-144.
|
[5] |
ZHAO Shuang, GU Rui, SONG Yanqing, WANG Xiangfeng, MIAO Qiuli.
Information Labeling in Instructions of Anti-tumor Drugs for Intravenous Infusion in a Hospital
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 978-980.
|
[6] |
WENG Lihong, GAO Huan, HU Xue, ZHANG Wenrui.
Infusion Requirements on Labels of 39 Chinese Traditional Medicine Injections
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(7): 437-440.
|
[7] |
LIU Min, HU Xue, LI Yanjiao, SONG Yanqing, WANG Xiangfeng.
Labeling of Instructions for Biopharmaceuticals for Intravenous Infusion
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(3): 165-168.
|
[8] |
ZHAO Shuang, SONG Yanqing, WANG Xiangfeng, JINFang, MIAO Qiuli.
Analysis of Pediatric Use Information in Package Inserts of Antineoplastic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(9): 555-560.
|
[9] |
JU Mengqi, YUAN Lijia, LV Xufeng, YANG Lina, YANG Yue.
Enlightenment of Market Share Liability on Compensation System for Delayed Drug Injury in China
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(7): 416-419.
|
[10] |
WANG Tao, LIU Songdong, WANG Dan.
Analysis and Consideration on Risks of Lysine Acetylsalicylate for Injection
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(5): 281-284.
|
[11] |
WANG Tao, WU Guizhi, DONG Duo.
Analysis and Consideration on Risk of Bromhexine Hydrochloride Injection
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(3): 171-173.
|
[12] |
HU Xue, ZHANG Yueming, LIU Xin, ZHANG Yongkai.
Investigation and Suggestion on Labeling of 75 Instructions for Intravenous Infusion Anti-infective Drugs
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(3): 168-170.
|
[13] |
WANG Tao, WANG Dan.
Risks Analysis of Gastrodin Injection
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 675-677.
|
[14] |
YU Jin-ran, WANG Hong-wei, WANG Yi-fang, YANG Yue.
Lifecycle Management of American Drug Labeling and Its Implication
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(6): 333-338.
|
[15] |
SUN Yu-xin, WEI Feng-fang, YANG Yue.
Study on Legal Responsibility of Drug Clinical Trials in America
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(7): 424-429.
|